159
Participants
Start Date
April 30, 2006
Primary Completion Date
June 30, 2008
Study Completion Date
August 31, 2008
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
New England Retina Consultants PC, West Springfield
Retina Diagnostic and Treatment Assoc., LLC, Philadelphia
Johns Hopkins Hospital School of Medicine, Baltimore
Charlotte Eye, Ear, Nose & Throat Asssociates, Charlotte
Southeast Retina Center, Augusta
Retina-Vitreous Associates, P.C., Nashville
Midwest Eye Institute, Indianapolis
Black Hills Regional Eye Institute, Rapid City
University of Chicago, Chicago
Dean A. McGee Eye Institute, Oklahoma City
Vitreoretinal Consultants Scurlock Tower Texas Medical Center, Houston
Medical Center Ophthamology, San Antonio
Associated Retina Consultants, Phoenix
Retina Centers, PC, Tucson
Retina Vitreous Associates Medical Group, Beverly Hills
Loma Linda University Health Care, Loma Linda
Retina Northwest PC, Portland
Ophthalmic Consultants of Boston, Boston
Collaborators (1)
Bayer
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY